 | Abatacept | | Hospital use only |
| Adalimumab syringe |
- TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- TA143 - Adalimumab, etanercept and infliximab for ankylosing spondylitis
- TA130 - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
- TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
| |
 | Allopurinol tablets | | |
| Anakinra (Kineret®) | | |
| Apremilast (Otezla®) | | |
 | Azathioprine | | Supported by ESCA |
| Baricitinib (Olumiant®) | | Hospital use only |
| Belimumab | | Hospital use only |
| Belimumab (Benlysta®) | | |
| Brodalumab (Kyntheum®) | | |
| Celecoxib capsules | | RICaD - CVD risk assessment in development |
| Certolizumab injection | | Hospital use only |
| Ciclosporin | | ESCA |
| Colchicine tablets | | |
| Diclofenac sodium dispersible tablets | | Very high relative cost. Short term use only. Swallowing difficulties. |
| Diclofenac sodium E/C tablets | | Short term use only |
| Diclofenac sodium injection | | Short term use only |
| Diclofenac sodium suppositories | | Short term use only |
| Etanercept syringe | | |
| Febuxostat tablets | | |
| Filgotinib (Jyseleca®) | | |
| Golimumab injection | | Hospital use only |
| Hydrocortisone acetate injection | | |
| Hydroxychloroquine tablets | | |
| Ibuprofen suspension | | If swallowing difficulties and paediatric use |
| Ibuprofen tablets | | |
| Indometacin capsules | | For gout and resistant case |
| Indometacin M/R capsules | | For gout and resistant case |
| Indometacin suspension (100ml) | | For gout and resistant case |
| Infliximab injection (Remicade®, Inflectra®, Remsima®) |
- TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- TA143 - Adalimumab, etanercept and infliximab for ankylosing spondylitis
- TA130 - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
- TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
| |
| Ketoprofen injection | | |
| Leflunomide tablets | | ESCA |
| Mefenamic acid capsules | | For dysmenorrhoea |
| Mefenamic acid tablets | | For dysmenorrhoea |
| Methotrexate 2.5mg tablets | | Supported with an ESCA. Methotrexate tablets - use 2.5mg strength ONLY. Methotrexate injection - Metoject is APC preferred brand. Check cytotoxic disposal arrangements locally. |
| Methotrexate injections | | Supported with an ESCA. Metoject is APC preferred brand. Check cytotoxic disposal arrangements locally. |
| Methylprednisolone acetate | | |
| Methylprednisolone/lidocaine injection | | |
| Naproxen tablets | | |
| Penecillamine tablets | | ESCA |
| Prednisolone tablets | | Plain tablets (not enteric coated). Second line in gout. |
| Probenecid tablets | | Hospital use only |
| Rasburicase injection | | |
| Ritumixab infusion (Mabthera®, Truxima®) | | |
| Sulfasalazine | | ESCA |
| Sulindac tablets | | Polyhydramnios (women only) |
| Tocilizumab (Tyenne® Roactemra®) | | Hospital use only |
| Triamcinolone injection | | |
| Upadacitinib (Rinvoq®) | | |
| Ustekinumab | | Hospital use only |
